ADAR1 is involved in a potent antiviral pathway that eliminates HCV RNA through adenosine to inosine editing, explaining HCV replicon clearance by IFN-alpha in vitro.
No takes yet. Share an insight, caveat, or question.
ADAR1 limits HCV replicon replication; leaves open whether modulating this pathway offers antiviral strategies in vivo.
Taylor et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: